Crystalline solid forms of the acetate salt of (1s,3s,4r)-4-((3as,4r,5s,7as)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1h-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol

Abstract

The present invention is generally directed to methods of using novel crystalline forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol and pharmaceutical compositions comprising same.

What is claimed is: 
     
         1 . A composition comprising a pharmaceutically acceptable excipient, carrier and/or diluent and a crystalline form of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol, designated as Compound 1 Form A, characterized by an X-ray powder diffraction pattern containing the following peaks: 6.0, 8.9, 10.7, 13.3 and 15.8 degrees 2Θ±0.3 degrees 2Θ. 
     
     
         2 . A composition comprising a pharmaceutically acceptable excipient, carrier and/or diluent and a crystalline form of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol, designated as Compound 1 Form B, characterized by an X-ray powder diffraction pattern containing the following peaks: 5.5, 9.4 and 12.2 degrees 2Θ±0.3 degrees 2Θ. 
     
     
         3 . A method for modulating SHIP1 activity in a mammal comprising administering an effective amount of Compound 1 Form A of  claim 1  or an effective amount of a composition of  claim 1  to the mammal in need thereof. 
     
     
         4 . A method for modulating SHIP1 activity in a mammal comprising administering an effective amount of Compound 1 Form B of  claim 2  or an effective amount of a composition of  claim 2  to the mammal in need thereof. 
     
     
         5 . A method for treating a disease, disorder or condition associated with SHIP1 activity in a mammal comprising administering an effective amount of Compound 1 Form A of  claim 1  or an effective amount of a composition of  claim 1  to the mammal in need thereof. 
     
     
         6 . A method for treating a disease, disorder or condition associated with SHIP1 activity in a mammal comprising administering an effective amount of Compound 1 Form B of  claim 2  or an effective amount of a composition of  claim 2  to the mammal in need thereof.